Keros Therapeutics’ (KROS) “Buy” Rating Reiterated at HC Wainwright
Keros Therapeutics (NASDAQ:KROS – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 298.41% from the stock’s previous close. KROS […]
Keros Therapeutics (NASDAQ:KROS – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 298.41% from the stock’s previous close. KROS […]
